Entos Pharmaceuticals
Edmonton
About Entos Pharmaceuticals
Entos develops next-generation genetic medicines using their proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Last round: Grant (Jan 2026)
- Website: entospharma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/entos-pharmaceuticals-19029 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.